Moderna’s RSV vaccine received FDA approval to expand its use to include certain younger adults aged 18 to 59 at increased risk for RSV infection. This regulatory expansion follows recent changes in agency leadership. The broader approval aims to address RSV disease burden in adult populations beyond the elderly.